Filing Flows › Comparisons › JUNS vs IBO
Jupiter Neurosciences vs Impact Biomedical: JUNS and IBO compared
Jupiter Neurosciences is the larger company: $24K of revenue in its latest quarter (Q2 2026) against $21K for Impact Biomedical (Q3 2026).
Where the money goes: JUNS and IBO
Jupiter Neurosciences (JUNS) · Q2 2026
Jupiter Neurosciences, Q2 2026: revenue $24K, net loss $2.3M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
Impact Biomedical (IBO) · Q3 2026
Impact Biomedical, Q3 2026: revenue $21K (+17% year over year), net loss $644K, operating cash flow $11K. The chart follows the revenue to costs, profit and cash.
| Jupiter Neurosciences (JUNS) | Impact Biomedical (IBO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $24K | $21K |
| Revenue growth, Y/Y | — | +17% |
| Operating margin | n/m | n/m |
| Net earnings | −$2.3M | −$644K |
| Operating cash flow | −$2.3M | $11K |
Questions
Which is bigger, Jupiter Neurosciences or Impact Biomedical?
Jupiter Neurosciences is the larger company: $24K of revenue in its latest quarter (Q2 2026) against $21K for Impact Biomedical (Q3 2026).
More: Jupiter Neurosciences earnings · how Jupiter Neurosciences makes money · Impact Biomedical earnings · how Impact Biomedical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.